Epmedin C
Based on 6 publication(s) in Google Scholar
Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of CDK2/Cyclin E. Epmedin C also upregulates Nrf2 expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia.
For research use only. We do not sell to patients.
- Purity: 99.47%
- CAS No.: 110642-44-9
- Formula: C39H50O19
- Molecular Weight:822.80
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Epmedin C
MoreAll Caspase Isoforms
More
Biological Activity
|
CDK2/cyclinE |
Epmedin C (0.1-10 μg/mL; 48 h) shows no cytotoxicity against RAW264.7, THP-1 and HD11 cells, and at the concentration of 1 μg/mL, it reduces the cytotoxicity induced by Deoxynivalenol (HY-N6684) in the aforementioned cell lines[2].
Epmedin C (1 μg/mL; 48 h) reduces Deoxynivalenol (DON)-induced cell death in RAW264.7, THP-1 and HD11 cells as measured by LDH release assay, including inhibition of ROS accumulation, caspase-1 activation, and secretion of proinflammatory cytokines (IL-1β, IL-6) in HD11 chicken macrophages[2].
Epmedin C (1 μg/mL; 48 h) promotes antibody production in mouse hybridoma cells and reverses the antibody inhibitory effect induced by DON. In iBMDM cells, it inhibits the DON-induced macrophage-mediated suppression of antibody production in co-cultured mouse hybridoma cells[2].
Epmedin C upregulates the expression level of Nrf2 mRNA by 23-50% in HaCaT cells treated with H2O2[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7, THP-1, HD11 macrophage cell lines
-
Concentration:0.1-10 μg/mL (alone); 1 μg/mL (cotreated with 600 ng/mL Deoxynivalenol (HY-N6684))
-
Incubation Time:48 h
-
Result:Showed no cytotoxicity at concentrations up to 10 μg/mL in all three cell lines.
Attenuated DON-induced cytotoxicity even when DON concentrations reached 0.8 μg/mL in RAW264.7 cells and 1.5 μg/mL in THP-1 and HD11 cells at 1 μg/mL.
Alleviated DON-induced LDH release, effectively reducing cell death when DON reached 0.8 μg/mL in RAW264.7 cells and 1.5 μg/mL in THP-1 and HD11 cells.
-
Cell Line:Mouse hybridoma cell lines
-
Concentration:1 μg/mL (alone or cotreated with 200 ng/mL Deoxynivalenol (HY-N6684))
-
Incubation Time:48 h
-
Result:Significantly promoted antibody production in hybridoma cells.
Restored antibody production that was inhibited by DON treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sanhuang chickens (female, one-day-old)[2]
-
Dosage:10 mg/kg
-
Administration:dietary supplementation; daily; 30 days
-
Result:Restored body weight to levels matching the control group at the end of the 30-day period.
Reduced feed conversion rate to control levels and increased voluntary feed intake compared to the Deoxynivalenol (DON)-only group.
Normalized liver and bursa of Fabricius organ coefficients.
Reduced red blood cell infiltration and lymphopenia in the spleen and thymus, and restored lymphocyte density in the bursa of Fabricius.
Restored villus height in the duodenum and ileum, reduced crypt depth in the duodenum and jejunum, and normalized cecal goblet cell arrangement; increased villus height in the duodenum and jejunum and reduced crypt thickness in the duodenum and ileum compared to the control group.
Completely reversed DON-induced suppression of IBV, NDV, H9, and MDV antibody titers.
Restored DON-reduced IgG levels at 33 days of age and IgM levels at 17 days of age.
Reduced DON-increased serum IL-1β levels at 17 and 33 days of age.
Inhibited DON-induced elevation of splenic caspase-1 activity to control levels.
Chemical Information
-
CAS No. 110642-44-9
-
Appearance Solid
-
Molecular Weight 822.80
-
Formula C39H50O19
-
Color Light yellow to yellow
-
SMILES
O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC2=CC(O)=C(C(C(O[C@H]3[C@H](O[C@]4([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@H](O)[C@@H](O)[C@H](C)O3)=C(C5=CC=C(OC)C=C5)O6)=O)C6=C2C/C=C(C)/C)[C@@H]1O
-
Synonyms
Epimedin-C; Baohuoside-VI
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 May 31:489:144992. PMID: 40466530 -
Heliyon
Epimedin C alleviated osteoarthritis development by regulating chondrocyte Nrf2-mediated NLRP3 inflammasome axis. [Abstract]2024 Nov 15;10(23):e40458. PMID: 39687146 -
J Nat Prod
Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation. [Abstract]2023 Sep 22;86(9):2091-2101. PMID: 37625387 -
J Pharm Pharmacol
Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway. [Abstract]2024 May 3;76(5):499-513. PMID: 37971302 -
PLoS One
Epimedin C enhances mitochondrial energy supply by regulating the interaction between MIC25 and UBC in rodent model. [Abstract]2025 May 28;20(5):e0325031. PMID: 40435285
Solvent & Solubility
DMSO : 250 mg/mL (303.84 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhou HR, et al. Jinlida Granules Reduce Obesity in db/db Mice by Activating Beige Adipocytes. Biomed Res Int. 2022;2022:4483009. Published 2022 May 19. [Content Brief]
[2]. Bu W, et al. Epmedin C Alleviates Deoxynivalenol-Induced Immunotoxicity by Inhibiting Caspase-1 Activation in Chicken Macrophages. J Agric Food Chem. 2025;73(37):23617-23632. [Content Brief]
[3]. Zheng M, et al. Ruhe Sanjie Tablet ameliorates depression-associated mammary gland hyperplasia by modulating estrogen receptor signaling and CDK2. J Ethnopharmacol. 2026;359:121025. [Content Brief]
[4]. Huang Z, et al. Virtual Screening of Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and In Vitro Validation. Molecules. 2025;30(8):1815. Published 2025 Apr 17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2154 mL | 6.0768 mL | 12.1536 mL | 30.3841 mL |
| 5 mM | 0.2431 mL | 1.2154 mL | 2.4307 mL | 6.0768 mL | |
| 10 mM | 0.1215 mL | 0.6077 mL | 1.2154 mL | 3.0384 mL | |
| 15 mM | 0.0810 mL | 0.4051 mL | 0.8102 mL | 2.0256 mL | |
| 20 mM | 0.0608 mL | 0.3038 mL | 0.6077 mL | 1.5192 mL | |
| 25 mM | 0.0486 mL | 0.2431 mL | 0.4861 mL | 1.2154 mL | |
| 30 mM | 0.0405 mL | 0.2026 mL | 0.4051 mL | 1.0128 mL | |
| 40 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7596 mL | |
| 50 mM | 0.0243 mL | 0.1215 mL | 0.2431 mL | 0.6077 mL | |
| 60 mM | 0.0203 mL | 0.1013 mL | 0.2026 mL | 0.5064 mL | |
| 80 mM | 0.0152 mL | 0.0760 mL | 0.1519 mL | 0.3798 mL | |
| 100 mM | 0.0122 mL | 0.0608 mL | 0.1215 mL | 0.3038 mL |